Clinical Trial

Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to explore a superior first-line induction remission regimen by incorporating Chidamide into the modified VAH chemotherapy combined with targeted therapy regimen, leveraging its dual epigenetic modulation mechanism.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-08.
Trial Details
NCT Number NCT07643636
Lead Sponsor Dongguan People's Hospital
Conditions AML (Acute Myeloid Leukemia)
Enrollment 46 participants
Start Date 2026-06-30
Primary Completion 2028-06-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-18